VIEMED HEALTHCARE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VIEMED HEALTHCARE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $270.28M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $224.26M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $183.01M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $138.83M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $117.06M | Mar 2, 2023 |
| FY2020 | Dec 31, 2020 | $31.20M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $33.45M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $42.85M | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | $23.81M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $21.45M | Mar 3, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.46M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $133.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $112.78M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $84.68M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $73.41M | Mar 2, 2023 |
| FY2020 | Dec 31, 2020 | $19.18M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $19.45M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $25.93M | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | $15.55M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $14.24M | Mar 3, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.93M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $11.27M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $10.24M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $6.22M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $9.13M | Mar 2, 2023 |
| FY2020 | Dec 31, 2020 | $5.07M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $2.80M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $19.41M | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | $4.24M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $2.39M | Mar 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.95M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $17.90M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $14.33M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $8.25M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $11.58M | Mar 2, 2023 |
| FY2020 | Dec 31, 2020 | $5.27M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $4.04M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $12.86M | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | $4.62M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $2.69M | Mar 3, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.02M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.07M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $2.78M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $2.70M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $2.11M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $1.08M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $848.0K | Mar 3, 2021 |
| FY2019 | Sep 30, 2019 | $208.0K | Mar 4, 2020 |
| FY2019 | Jun 30, 2019 | $203.0K | Mar 4, 2020 |
| FY2019 | Mar 31, 2019 | $234.0K | Mar 4, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.37M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $106.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $87.88M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $68.16M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $54.89M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $52.83M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $41.38M | Mar 3, 2021 |
| FY2019 | Sep 30, 2019 | $10.23M | Mar 4, 2020 |
| FY2019 | Jun 30, 2019 | $11.52M | Mar 4, 2020 |
| FY2019 | Mar 31, 2019 | $9.46M | Mar 4, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.92M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $39.09M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $45.21M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $27.75M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $22.49M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $35.11M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $19.09M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $22.37M | Mar 4, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.99M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $37.77M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $26.09M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $22.90M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $19.74M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $13.04M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $13.39M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $6.11M | Mar 4, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.15M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $177.07M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $154.90M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $117.04M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $117.96M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $112.56M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $82.60M | Mar 3, 2021 |
| FY2019 | Sep 30, 2019 | $79.98M | Mar 4, 2020 |
| FY2019 | Jun 30, 2019 | $71.01M | Mar 4, 2020 |
| FY2019 | Mar 31, 2019 | $58.72M | Mar 4, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.63M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $43.77M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $41.00M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $19.95M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $23.14M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $30.87M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $38.90M | Mar 3, 2021 |
| FY2019 | Sep 30, 2019 | $39.66M | Mar 4, 2020 |
| FY2019 | Jun 30, 2019 | $34.88M | Mar 4, 2020 |
| FY2019 | Mar 31, 2019 | $24.83M | Mar 4, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.55M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $131.39M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $113.90M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $97.09M | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | $94.82M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $81.69M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $43.70M | Mar 7, 2022 |
| FY2019 | Sep 30, 2019 | $40.32M | Mar 4, 2020 |
| FY2019 | Jun 30, 2019 | $36.14M | Mar 4, 2020 |
| FY2019 | Mar 31, 2019 | $33.89M | Mar 4, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.94M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $32.99M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $29.77M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 6, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.89M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $89.69M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $79.50M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $69.85M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $73.34M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $65.64M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $34.11M | Mar 3, 2021 |
| FY2019 | Sep 30, 2019 | $31.72M | Mar 4, 2020 |
| FY2019 | Jun 30, 2019 | $28.87M | Mar 4, 2020 |
| FY2019 | Mar 31, 2019 | $27.55M | Mar 4, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.50M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $17.54M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $12.84M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $16.91M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $28.41M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $30.98M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $13.36M | Mar 3, 2021 |
| FY2019 | Sep 30, 2019 | $12.63M | Mar 4, 2020 |
| FY2019 | Jun 30, 2019 | $7.69M | Mar 4, 2020 |
| FY2019 | Mar 31, 2019 | $7.41M | Mar 4, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 3, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 3, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.02M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 39.13M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 38.51M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 38.05M | Mar 6, 2024 |
| FY2021 | Dec 31, 2021 | 39.64M | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | 39.19M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | 37.95M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 37.50M | Mar 4, 2020 |